In yesterday’s Wall Street session, Astrazeneca plc ADR (NASDAQ:AZN) shares traded at $63.17, down -1.44% from the previous session.
30 analysts cover Astrazeneca plc ADR (NASDAQ:AZN), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $105.95 and a low of $65.00, we find $79.87. Given the previous closing price of $64.09, this indicates a potential upside of 24.62 percent. AZN stock price is now -4.67% away from the 50-day moving average and -8.53% away from the 200-day moving average. The market capitalization of the company currently stands at $195.82B.
The stock has received a hold rating from 4 analysts and a buy rating from 24. Brokers who have rated the stock have averaged $81.11 as their price target over the next twelve months.
With the price target enhanced from $66.50 to $80, Jefferies Upgraded its rating from Hold to Buy for Astrazeneca plc ADR (NASDAQ: AZN).
A total of 0.05% of the company’s stock is owned by insiders.
On Friday morning Astrazeneca plc ADR (NASDAQ: AZN) stock kicked off with the opening price of $63.24. During the past 12 months, Astrazeneca plc ADR has had a low of $61.73 and a high of $76.56. As of last week, the company has a debt-to-equity ratio of 0.77, a current ratio of 0.79, and a quick ratio of 0.60. According to the stock market information, the enterprise value for the company is $214.47B, which is based on a 33.41 price-to-earnings ratio, a 2.59 price-to-earnings-growth ratio, and a beta of 0.52. The fifty day moving average price for AZN is $66.17 and a two-hundred day moving average price translates $69.05 for the stock.
The latest earnings results from Astrazeneca plc ADR (NASDAQ: AZN) was released for Sep, 2023. The net profit margin was 13.10% and return on equity was 16.30% for AZN. The company reported revenue of $11.49 billion for the quarter, compared to $10.98 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.64 percent.
Astrazeneca plc ADR(AZN) Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.